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A B S T R A C T
Redox-responsive nanoparticles were synthesized by desolvation of bovine serum albumin followed by
disulfide-bond crosslinking with N, N0-Bis (acryloyl) cystamine. Dynamic light scattering and
transmission electron microscopy studies revealed spherical nanoparticles (mean diameter: 83 nm,
polydispersity index: 0.3) that were glutathione-responsive. Confocal microscopy revealed rapid,
efficient internalization of the nanoparticles by Daoy medulloblastoma cells and healthy controls (HaCaT
keratinocytes). Cisplatin-loaded nanoparticles with drug:carrier ratios of 5%, 10%, and 20% were tested in
both cell lines. The formulation with the highest drug:carrier ratio reduced Daoy and HaCaT cell viability
with IC50 values of 6.19 and 11.17 mg mL1, respectively. The differential cytotoxicity reflects the cancer
cells’ higher glutathione content, which triggers more extensive disruption of the disulfide bond-
mediated intra-particle cross-links, decreasing particle stability and increasing their cisplatin release.
These findings support continuing efforts to improve the safety and efficacy of antineoplastic drug
therapy for pediatric brain tumors using selective nanoparticle-based drug delivery systems.
© 2016 Elsevier B.V. All rights reserved.
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Medulloblastomas (MBs) are among the primary brain tumors
most frequently diagnosed in pediatric patients. They occur mainly
in infants and children but occasionally also adolescents (or even
adults). MBs arise in the posterior fossa and fourth ventricle and
have a high propensity to metastasize (Coluccia et al., 2016;
Morfouace et al., 2014). Most MBs are still treated with the
combined use of aggressive surgical resection followed by multi-
agent chemotherapy and, for children over 3 years of age,
craniospinal irradiation. Although this approach has considerably
improved the 5-year survival rates of patients with MBs, the
treatments themselves frequently cause acute and/or long-term* Corresponding author at: Department of Pharmacy Health and Nutritional
Science, University of Calabria, Edificio Polifunzionale, 87036 Rende, Italy.
E-mail address: manuela.curcio@unical.it (M. Curcio).
1 These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.ijpharm.2016.12.017
0378-5173/© 2016 Elsevier B.V. All rights reserved.adverse effects, many of which severely diminish the survivors’
quality of life (Matheson et al., 2016; Nageswara Rao et al., 2014).
For the past 20 years (Parhizkar et al., 2016), the alkylating
agent cisplatin (CPT) has been a mainstay of MB chemotherapy.
However, its high toxicity often results in major adverse effects,
including stunted growth, irreversible hearing loss, and renal
dysfunction. These features severely limit the CPT doses that can be
used and consequently the therapeutic benefits that can be
achieved in children with MB (Dhar et al., 2008; Nageswara Rao
et al., 2014; Wehe et al., 2014).
Increasingly dynamic collaboration between oncologists, biol-
ogists, and material scientists has generated a number of proposals
for improving the safety and efficacy of brain tumor chemotherapy
regimens (Gharpure et al., 2015; Kim et al., 2010; Pacardo et al.,
2015; Stylianopoulos and Jain, 2015; Wang et al., 2012). One of the
most versatile options involves the use of nanoscale polymeric
carriers (Eetezadi et al., 2015; Fernandes et al., 2015; Johnstone
et al., 2016): they offer a high surface area for drug binding and
controllable physical-chemical and biologic properties, which can
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improving its pharmacokinetics, therapeutic index, and safety
profile (Kumari et al., 2016). Several nanoparticles have also been
shown to cross the BBB and accumulate in the CNS (Calvo et al.,
2001; Ulbrich et al., 2009), essential requisites for carriers destined
for use in the treatment of brain tumors.
Human and bovine albumin have both been widely used to
create nanoparticle systems for delivering drugs to a variety of
organs. The advantages of albumin include a high drug-binding
capacity (Elzoghby et al., 2012), biodegradable and biocompatible
properties, and the fact that it already has U.S. Food and Drug
Administration approval for pharmaceutical applications (Raval
et al., 2015). The hyperpermeability of intratumoral blood vessels
enhances the delivery of albumin nanoparticles (A-NP) to
neoplastic tissues, where they are readily taken up by cancer
cells to meet their increased need for amino acids and energy
(Neumann et al., 2010). A-NP accumulation in these cells is also
promoted by the reduced venous clearance of most solid tumors
(Noguchi et al., 1998). Importantly, several unmodified A-NPs have
been shown to cross the BBB via adsorptive transcytosis triggered
by electrostatic interactions between the polycationic proteins and
the negatively charged brain membrane (Hervé et al., 2008), and
their use is not associated with any impairment of locomotor,
explorative, or cognitive functions (Bergonzi et al., 2016).
Carriers capable of responding to specific conditions within a
cell, such as changes in the redox state, pH, or enzyme activity
profile, can enhance a drug’s efficacy and specificity while
significantly reducing its side effects (Qiu and Park, 2012). Solid
tumors, for example, frequently present elevated levels of the
master antioxidant, glutathione (GSH) (Ilangovan et al., 2002),
which can be exploited to trigger targeted release of anticancer
drugs. GSH-responsive delivery can be achieved by using N, N0-bis
(acryloyl)cystamine (BAC) as a disulfide-bond-containing cross-
linker in the formation of NPs from naturally occurring polymers
(e.g. chitosan and chitosan derivatives). In the presence of high
GSH levels, the disulfide bridges within the polymer network
undergo reduction, a reaction which destabilizes the NP and
increases the release of the drug they are carrying (Curcio et al.,
2015b).
In literature, several examples of redox-responsive materials
based on serum albumin are presented. Wang et al. prepared a self-
cross-link strategy to fabricate HSA nanoparticles stabilized by
intermolecular disulfide bonds and dissolvable in reducing media
(Wang et al., 2013a). In a work of 2015 (Shi et al., 2015), pH- and
redox-sensitive nanoparticles were prepared by covalent linkage of
a PtIV prodrug to human serum albumin (HSA) to form a disulfide
containing Pt-HSA complex, followed by conjugation to calcium
phosphate (CaP) nanoparticles. Upon cellular uptake, CaP is
decomposed with pH < 6.0, releasing Pt-HAS, while the PtIV
prodrug is dissociated from HSA in the form of cisplatin after
disulfide reduction by GSH. Adriamycin was also linked to HSA
using a disulfide-containing spacer to obtain an amphiphilic
specimen able to form micellar-like nanoparticles in which the
drug release was controlled by GSH concentration (Chen et al.,
2015).
Finally, Molina et al. employed a nanoprecipitation method to
obtain HSA nanoparticles decorated with the photosensitizer
chlorin e6. The nanoparticles were stabilized using disulfide-
containing cross-linker to create a smart drug delivery system that
is activated only upon nanoparticles degradation in the reducing
intracellular environment (Molina et al., 2016).
In this study, we developed and tested redox-responsive bovine
serum albumin (BSA)-nanoparticles (RNPs) for use in the delivery
of CPT to MB cells. The RNPs were synthesized by means of a de-
solvation technique in which BAC was used as GSH-responsive
cross-linker. We used transmission electron microscopy (TEM) formorphological characterization of the RNPs and dynamic light
scattering (DLS) to assess their size distribution and redox
responsivity. To assess the applicability of these RNPs for the
treatment of MB, we measured their in vitro cytotoxicity in healthy
human keratinocyte (HaCaT) and human MB (Daoy) cell lines.
Finally, confocal microscopy was used to confirm the effective
uptake of the RNPs by both cell lines.
2. Materials and methods
2.1. Materials
The following reagents were purchased from Sigma Aldrich (St
Louis, MO): bovine serum albumin (BSA), cystamine dihydro-
chloride, acryloyl chloride, fluorescein-5-isothiocyanate (FITC),
cisplatin (CPT), glutathione (GSH), NaOH, NaCl, reagent-grade
ethanol, reagent-grade dimethyl sulfoxide (DMSO), paraformalde-
hyde (PFA), Triton X-100, Dulbecco’s Modified Eagle Medium
(DMEM), phosphate-buffered saline (PBS), sodium carbonate
buffer, 200 mM glutamine (Gln), 100 mM sodium pyruvate, 100
non-essential amino acids (NEAA), and antibiotic solution
(100 units mL1 penicillin and 10000 mg mL1 streptomycin) were
from Sigma Aldrich (St Louis, MO). Minimum Essential Media
(MEM) and fetal bovine serum (FBS) were from Gibco-Invitrogen
(Carlsbad, CA). Phalloidin was from Thermo Scientific (Waltham,
MA, USA). The CellTiter 96 AQueous One Solution Cell Proliferation
assay was from Promega (Madison, WI, USA).
2.2. Cell culture
Human keratinocytes (HaCaT) and human MB (Daoy) cells
purchased from ATCC were cultured at 37 C in a humidified 5% CO2
incubator. Briefly, HaCaT cells were grown in DMEM supplemented
with 10% FBS, 2 mM Gln, and 100 units mL1 antibiotic solution.
Daoy cells were maintained in MEM supplemented with 10% FBS,
1 mM sodium pyruvate, 1 NEAA, and 100 units mL1 of antibiotic
solution.
2.3. Synthesis of N, N0-Bis (acryloyl) cystamine (BAC)
BAC was prepared as described elsewhere (Sun et al., 2010).
Briefly, 50 mL of an aqueous solution (1.0 M) of cystamine
dihydrochloride was placed in a 250 mL three-neck flask equipped
with a thermometer and two 50-mL dropping funnels. Then, 10 mL
acryloyl chloride solution in dichloromethane (15.0 M) and 20 mL
NaOH aqueous solution (10.0 M) were simultaneously added,
dropwise, at 0–5 C and allowed to react at room temperature (RT)
for 16 h. The BAC thus obtained was purified by recrystallization
from ethyl acetate. The reaction yield was 73% ca.
2.4. Synthesis of FITC-BSA
BSA was labeled with FITC, as previously described (Ke et al.,
2015). BSA (60 mg) was dissolved in 3.0 mL sodium carbonate
buffer (100 mM, pH 9.2), and 0.6 mL FITC solution in sodium
carbonate buffer (1.0 mg mL1) was then added and allowed to
react at RT for 3 h. The FITC-BSA thus obtained was purified by
dialysis against 5.0 mM phosphate buffer (pH 3.0) for two days.
2.5. Preparation of RNPs
RNPs were prepared using a previously described de-solvation
method with minor modifications (Wolak and Thorne, 2013). BSA
powder (200 mg) was added to 200 mL distilled water. The pH was
then adjusted to 10 with 0.1 M NaOH while the mixture was stirred
at 500 rpm, and the NaCl concentration was fixed at 10 mM. The
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dropwise at a rate of 1 mL min1 until the solution became just
turbid. Finally, 2.0 mL of the BAC–ethanol solution (10 mg mL1)
was added to induce intra-particle cross-linking. The solution was
stirred continuously at 500 rpm and 50 C for 48 h. The RNPs thus
obtained were purified by two 30-min cycles of centrifugation at
20,000g and re-dispersion in ethanol to remove unreacted
chemicals and free BSA molecules.
2.6. RNPs characterization
The morphological analysis was carried out by transmission
electron microscopy (TEM) using a Hitachi S-3500N microscope
(Hitachi Science Systems, Ltd., Ibaraki, Japan). RNP size and size
distribution were determined by dynamic light scattering (DLS)
analysis using a 90 Plus Particle Size Analyzer (Brookhaven
Instruments Corporation, New York, NY, USA) at 25.0  0.1 C.
The autocorrelation function was measured at 90 and the laser
beam was operating at 658 nm. The polydispersity index (P.I.) was
used as a measure of the size distribution. It was directly obtained
from the instrumental data fitting procedures using inverse
Laplace transformation and CONTIN methods. P.I. values < 3
indicate homogenous and mono-disperse populations (Curcio
et al., 2015c). The same methodology was employed for the
determination of the GSH-induced destabilization by incubating
RNPs in PBS (pH 7.4) solution in the absence or presence of GSH
(10 mM or 10 mM), for 24 h under stirring at RT.
2.7. Drug loading
CPT was loaded into RNPs as follows: in separate experiments,
25 and 50 mg of preformed empty NPs were wetted with 2.0 mL of
a concentrated drug solution (2.5 mg mL1). After 3 days, under
slow stirring at 25 C, the NPs were filtered and dried at reduced
pressure in the presence of P2O5 to a constant weight.
The loading efficiency percentage (LE%) was determined by
HPLC analysis of the filtered solvent according to the following
Eq. (1):
LE %ð Þ ¼ Ci  C0
Ci
ð1Þ
Here Ci and C0 were the concentrations of drug in the solution
before and after the loading study, respectively.
The drug loaded percent (DL%) was calculated according to the
following Eq. (2):
DLð%Þ ¼ CPTðmgÞ
RNPsðmgÞ  100 ð2Þ
The HPLC equipment consisted of a Jasco PU-2089 Plus liquid
chromatograph equipped with a Rheodyne 7725i injector (fitted
with a 20 mL loop), a Jasco UV-2075 HPLC detector operating at
254 nm, and a Jasco-Borwin integrator. A reversed-phase C18
column (mBondapak, 10 mm of 250  4.6 mm internal diameter
obtained from Waters) was used. The mobile phase consists of a
methanol:water:acetonitrile mixture (40:30:30 v/v/v), and 1.1 mL
min1 flow rate was maintained throughout the analysis (Kaushik
et al., 2010).
2.8. MTS assay
Cytotoxicity was evaluated by using the [3-(4,5-dimethylth-
iazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt, MTS] assay. HaCaT cells (10,000 cells/well)
and Daoy cells (4000 cells/well) were seeded in 100 mL of culture
medium in 96-well plates and incubated overnight at 37 C in 5%CO2. The medium was then removed, 100 mL of free CPT or freshly
prepared CPT-loaded RNPs were added, and the cells were
incubated for 24 h under standard conditions. To evaluate cell
toxicity, the medium was removed, the cells were washed twice
with PBS, and fresh culture medium (100 mL) was added. MTS
(20 mL) was added directly to culture wells, and the plates were
incubated for an additional 2 h at 37 C in 5% CO2. Absorbance at
490 nm was then measured by a microplate reader (Promega). Cells
cultured in fresh culture medium were used as negative controls,
while culture medium alone was used for blank correction.
2.9. Cellular uptake of RNPs
FITC-labeled RNPs prepared as described above were used to
assess cellular uptake. HaCaT cells (40,000 cells/well) and Daoy
cells (10,000 cells/well) were seeded in 300 mL of culture medium
in 8-well glass slides (Thermo Scientific, Waltham, MA, USA) and
incubated overnight at 37 C in 5% CO2. The cells were then
incubated with 32 ug/mL of FITC-labeled RNPs for 3 h. The cells
were then washed twice with PBS and fixed with 4% PFA for 10 min
at RT. After three washes with PBS, 5 min of incubation with 0.1%
Triton X-100, and three additional PBS washes, cells were stained
with phalloidin (1:100) for 15 min at RT. Nuclei were counter-
stained with Hoechst reagent. Slides were mounted and images
were acquired using a FV1200 MPE laser scanning confocal
microscope (Olympus) with an UPlanSAPO 40/0.95 NA objective.
Images were processed using Imaris 8.1 software (Bitplane, Zürich,
CH).
2.10. Statistical analysis
All experiments were performed in triplicate, and data reported
are the means  S.D. of three independent experiments. Statistical
analysis and plotting were performed with GraphPad Prism,
Version 6.0 (GraphPad Software Inc., San Diego, California). The
IC50 was calculated using a nonlinear regression analysis, the
sigmoidal four-parameter logistic curve (4PL). Two-way ANOVA
was used to assess the significance of the results, and p-values of
less than 0.05 were considered significant. Significance of IC50
values in HaCaT vs Daoy was determined with unpaired two-tailed
t-test.
3. Results
3.1. Synthesis and characterization of RNPs
The RNPs were prepared using a two-step procedure that
involved the creation of BSA nanoparticles with a desolvation
method and subsequent crosslinking with BAC. Because the
formation of RNPs was influenced by electrostatic attraction and
repulsion between BSA molecules, which varied with the pH and
ionic strength (Jun et al., 2011), desolvation was carried out at pH
10 and a NaCl concentration of 10 mM. The crosslinking process
involves a Michael-type addition reaction between the nucleo-
philic groups in the protein side chain (free amino, hydroxyl, and
thiol groups) and acrylic moieties of BAC (Fig. 1) (Curcio et al.,
2015b).
The RNPs were spherical with a narrow size range (mean
diameter: 83 nm, P.I. 0.3), as confirmed by combined TEM/DLS
studies (Figs. 2 and 3A). To investigate their GSH-responsivity,
additional DLS analyses were performed on the RNPs after 24 h
incubation in PBS alone (Fig. 3A) or PBS with two different
concentrations of GSH (pH 7.4): the 10 mM GSH concentration
(Fig. 3B) was used to mimic that of the extracellular matrix, and the
10 mM GSH solution (Fig. 3C) was employed as a model for
intracellular environment of cancer cells. The size range of the
Fig. 1. Schematic representation of RNPS synthesis. A) Synthesis of N, N0-Bis (acryloyl) cystamine (BAC); B) Synthesis of RNPs by desolvation.
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lower-concentration solution (Fig. 3A and 3B, respectively). In
contrast, in the presence of GSH 10 mM, the mean diameter and P.I.
of the RNPs increased significantly (to 167 nm and 0.47), changes
that could be attributed to the rupture of crosslinking points in
RNPs and consequent swelling of the network.
3.2. Biocompatibility of RNPs
The Daoy human MB cell line was used in experiments designed
to assess the efficacy of the RNPs as drug-delivery vehicles for
treating MB. HaCaT cells, a spontaneously transformed keratino-
cyte cell line, were employed to test RNP toxicity on healthy cells
(Wolff et al., 2013; Laner-Plamberger et al., 2013). Cells of bothFig. 3. DLS analysis of RNPs after 24 h incubation in PBS 0.1 M, pH 7.4 (A)
Fig. 2. TEM micrographs of RNP3.types were incubated for 24 h with empty RNPs at concentrations
ranging from 12.5 103 to 1.6 mg mL1. HaCaT cells displayed no
appreciable reductions in viability at any of the RNP concentrations
tested (Fig. 4A), indicating that the RNPs are likely to be safe drug; GSH 10 mM in PBS 0.1, pH 7.4 (B), GSH 10 mM in PBS 0.1, pH 7.4 (C).
Fig. 4. Cytocompatibility of unloaded RNPs in HaCaT (A) and Daoy (B) cells. Cell
viability was measured by MTS assay after 24 h of incubation.
Table 1
IC50 valued for CPT and CPT nanoformulations on HaCaT and Daoy cell lines after
24 h incubation.
Sample DL(%) Cell Lines IC50 (mg mL1) Two-tailed p-value
HaCaT vs DAOY
CPT – HaCaT 3.71 P < 0.01
DAOY 2.42
RNP2 10 HaCaT 15.24 P < 0.0001
DAOY 8.82
RNP3 20 HaCaT 11.17 P < 0.0001
DAOY 6.19
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detected in Daoy cells (Fig. 4B), confirming the complete
biocompatibility of RNPs.
3.3. Cytotoxicity studies of CPT-loaded RNPs
Since our intention was to use the RNPs as carriers for CPT, our
next step was to evaluate the cytotoxic profiles of free CPT in the
two cell lines. As shown in Fig. 5A and C, both HaCaT and Daoy cells
proved to be CPT-sensitive (Ho et al., 2016; Luong et al., 2016) with
IC50 values of 3.71 and 2.42 mg mL1, respectively (Table 1). With
the aim of enhancing the drug’s therapeutic index, selected
amounts of RNPs were soaked in aqueous CPT solutions to produce
drug:carrier ratios up to 20%. (Significantly higher ratios cannot be
achieved by further increases in the CPT concentration of the
soaking solution.) In all cases, loading efficiencies were close to
100%. Three formulations were obtained with final drug:carrier
ratios of 5% (CPT:RNP1), 10% (CPT:RNP2), and 20% (CPT:RNP3).
These three CPT nanoformulations were incubated with HaCaT
or Daoy cells at doses calculated to produce equivalent CPT
concentrations in the range 0–16 mg mL1. Twenty-four hours
later, cell viability was assessed. As shown in Fig. 5B and D,
compared with free CPT (Fig. 5A and C), CPT:RNP2 and CPT:RNP3
displayed lower toxicity in both cell lines, but Daoy cell viability
was clearly reduced more than that of the normal keratinocyte line.
In contrast, the formulation with the lowest drug:carrier ratio, CPT:
RNP1, produced excessively low rates of killing in both cell lines
(data not shown).
3.4. Cellular uptake of FITC-RNPs
Effective cellular uptake is a key requisite for any cell-
responsive nano-carrier. To assess this aspect, we labeled our
RNPs with FITC, incubated them with HaCaT and Daoy cells (cell
nuclei and cytoskeletons were stained with Hoechst blue and
phalloidin-Cy5 orange, respectively) for 3 h, and examined FITC-
RNPs uptake by confocal microscopy confirming that their
internalization occurs rapidly and with high efficiency. In
Fig. 6A and B the dichroic (DIC) overlay shows the DIC image
merged with the confocal fluorescent image of a single xy plane.Fig. 5. Cytotoxicity of different concentrations of free CPT (0–10 mg mL1) and two CPT n
Daoy (B and D) cells. * p < 0.05, ** p < 0.01 RNP2 vs RNP3.Orthogonal views of the xy, xz and yz single planes at the indicated
orthogonal xyz axes (white lines) of HaCaT and Daoy cells (Fig. 6C
and D) shows the localization of FITC-loaded RNPs relative to
subcellular compartments, while the three-dimensional recon-
structions from 17 planes highlight the intracellular localization of
FITC-loaded RNPs relative to the surfaces HaCaT and Daoy cells.
(Fig. 6E and F).
4. Discussion
The aims of our study were to evaluate the in vitro efficacy and
safety of CPT-loaded RNPs for the treatment of MBs. As shown in
Fig. 1, the BSA RNPs we synthesized were cross-linked with BAC.
From a chemical point of view, the reaction we planned involves
the addition of a nucleophile to an activated electrophilic olefin
under mild reaction conditions. This offers the advantages of high
functional group tolerance and versatility (Mather et al., 2006). The
decision to crosslink the RNPs with BAC, which stabilizes the RNPs
by the formation of disulfide bonds, allowed us to obtain RNPs that
were responsive to the redox status of the intracellular environ-
ment. Because the RNPs were designed for use in the treatment of
MBs, we used TEM/DLS to confirm that they were small enough to
effectively penetrate the blood-brain barrier (BBB) (Fig. 2).
A key requirement for any drug-delivery vehicle is the complete
absence of negative effects on the viability of healthy cells (Curcio
et al., 2015d). We therefore tested the activity of empty RNPs at
concentrations ranging from 12.5 103 to 1.6 mg mL1. As shown inanoformulations, RNP2 (dash lines) and RNP3 (solid lines), on HaCaT (A and C) and
Fig. 6. Confocal images acquired in stacks to allow 3D reconstruction of HaCaT (A, C and E) and Daoy (B, D and F) cells incubated for 3 h with FITC-loaded RNPs. Scale bars,
5 mm.
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ble in both cell models.
CPT displays strong cytotoxic activity in many solid tumors,
including testicular, ovarian, breast, bladder, lung, and head and
neck cancer (Parhizkar et al., 2016). Together with radiation, it has
played a pivotal role in the treatment of MB for the past two
decades. However, its clinical efficacy is limited by the severe side
effects it produces (Dhar et al., 2008).
Having confirmed the CPT-sensitivity of Daoy and HaCaT cells,
we assessed their responses to two CPT nano-formulations with
drug:carrier ratios of 10% (CPT:RNP2) and 20% (CPT:RNP3). The
cytotoxicity of CPT loaded into RNPs is strongly influenced by the
intracellular GSH levels (Wang et al., 2013b), which are higher in
cancer cells than in normal cells (Curcio et al., 2015a). RNPs
internalized by the Daoy cells therefore undergo enhanced
disruption of their BAC crosslinking points, which leads to more
marked increases in RNP size, the release of greater amounts of CPT
into the intracellular environment, and more evident cytotoxicity
than that produced in HaCaT cells, as reflected by the IC50 values in
Table 1. These data clearly show that free CPT is less effective in
killing HaCaT cells, where its IC50 is 1.53 times higher than that
recorded for Daoy cells. The difference is even more marked when
CPT nano-formulations are used: the IC50 values for CPT:RNP2 and
CPT:RNP3 in the HaCaT cells are 1.73 and 1.80 times higher,
respectively, than those recorded in Daoy cells. This effect can be
attributed to the fact that the size of the RNPs is relatively
unaffected by the lower GSH concentrations that are typical of
HaCaT cytosol (see DLS analyses), and under these conditions theamount of CPT released by the NPs (and consequently, its
cytotoxicity) is appreciably reduced.
It should be highlighted that, due to the higher drug:carrier
ratio, RNP3 displayed more intense cytotoxicity than RNP2, as
reflected by lower IC50 values. More interestingly, RNP3 showed
higher selectivity for the neoplastic cells than free CPT, as a results
of their capability to modulate the release of cytotoxic drug into
cancer cells, increasing its intracellular concentration.
5. Conclusions
In this study we proposed a novel approach for Medulloblasto-
ma treatment based on the redox-responsive delivery of cisplatin
by bovine serum albumin nanoparticles. A two steps procedure
consisting of desolvation and crosslinking with N, N0-Bis (acryloyl)
cystamin processes was employed for the preparation of RNP with
dimensional range in the nanoscale and a narrow dimensional
range. The core results of the study is the possibility to modulate
the efficiency of the cytotoxic drug as a function of the intracellular
GSH content. At high GSH content, the crosslinker is cleaved
promoting the RNP destabilization and thus the drug release. As a
consequence, higher toxic effect is recorded in Daoy against HaCaT
cell lines, with an enhancement of the therapeutic index.
Although the promising results of our study are undeniably
preliminary, they provide encouraging support for continuing
efforts to develop more cell-specific delivery systems for
antineoplastic drugs, particularly those used to treatment tumors
in highly vulnerable tissues like those of the CNS.
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